Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.47 -1.26 (-0.80%)
Official Closing Price Updated: 4:10 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Critical Insights From Johnson & Johnson Analyst Ratings: What You Need To Know
Via Benzinga
Analyzing NYSE:JNJ's Dividend Potential.
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock. 
Via Chartmill
Is Johnson & Johnson the Best Dividend Stock for You?
You won't find a more dependable dividend payer on Wall Street. But whether it's the best stock for you depends on other factors. 
Via The Motley Fool
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Via The Motley Fool
Will JOHNSON & JOHNSON Break Out? A Technical Analysis Perspective.
A technical analysis of JOHNSON & JOHNSON (NYSE:JNJ) shows it may be setting up for a breakout. 
Via Chartmill
Competitor Analysis: Evaluating Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster than regular tablets. A federal judge ruled the claims were preempted by FDA... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
JNJ appears to be in the latter stages of wave {iii} of 1. 
Via Talk Markets
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Johnson & Johnson (NYSE:JNJ) achieves Golden Cross, signaling shift to bullish trend. Stock at $164.43, above all key moving averages & with positive catalysts ahead. 
Via Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
Via Benzinga
Exposures Product Safety
12 Dividend Stocks to Earn Income Every Month
Get paid a dividend on a monthly basis. 
Via The Motley Fool
Is Johnson & Johnson Stock a Buy?
The company hasn't performed well in recent years, 
Via The Motley Fool
Johnson & Johnson Unusual Options Activity
Via Benzinga
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
There's no reason to succumb to gloom and doom here. 
Via The Motley Fool
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the... 
Via Benzinga
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic. 
Via Benzinga
Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?
Now could be a great time to buy excellent dividend stocks, but these two ETFs have different approaches. 
Via The Motley Fool
Topics ETFs
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
This relative unknown hasn't missed a dividend payment to its shareholders in more than 200 years! 
Via The Motley Fool
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
Johnson & Johnson announced major changes to its 340B pricing for Stelara and Xarelto, effective October 15. Disproportionate share hospitals will need to purchase these drugs at full price initially... 
Via Benzinga
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
Johnson & Johnson is negotiating with plaintiffs' lawyers opposing its $6.48 billion talc settlement, 
Via Benzinga
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
From Johnson & Johnson
Via Business Wire
2 Unstoppable Stocks That Are Screaming Buys in August
These stocks have quality businesses behind them. 
Via The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
Some of Trump's Dividend Kings deserve a crown more than others. 
Via The Motley Fool
Topics Government
Exposures Political
A Big CEO Move, Big Buffett Buys, and More
Motley Fool analysts talk over market news including earnings updates from Home Depot, Walmart, and Brinker. 
Via The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
This leading pharmaceutical stock is flying under the radar right now. 
Via The Motley Fool
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo... 
Via Benzinga
Exposures Product Safety
4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt
Shield your investments from market volatility with these four resilient defensive stocks, offering stability and potential growth despite uncertainty. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Johnson & Johnson to Acquire V-Wave
From Johnson & Johnson
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.